Moderna Inc (NASDAQ:MRNA) shares traded -6.51% lower at $34.17 on Wall Street last session.
MRNA stock price is now -15.79% away from the 50-day moving average and -58.36% away from the 200-day moving average. The market capitalization of the company currently stands at $13.15B.
With the price target reduced from $99 to $51, Goldman Downgraded its rating from Buy to Neutral for Moderna Inc (NASDAQ: MRNA). , while ‘BofA Securities’ rates the stock as ‘Underperform’
In other news, Klinger Shannon Thyme, Chief Legal Officer sold 529 shares of the company’s stock on Dec 09 ’24. The stock was sold for $23,637 at an average price of $44.68. Upon completion of the transaction, the Chief Legal Officer now directly owns 20,446 shares in the company, valued at $0.7 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Dec 09 ’24, Officer Klinger Shannon Thyme bought 529 shares of the business’s stock. A total of $23,637 was incurred on buying the stock at an average price of $44.68. A total of 10.82% of the company’s stock is owned by insiders.
During the past 12 months, Moderna Inc has had a low of $31.94 and a high of $170.47. As of last week, the company has a debt-to-equity ratio of 0.11, a current ratio of 4.39, and a quick ratio of 4.20. The fifty day moving average price for MRNA is $40.6394 and a two-hundred day moving average price translates $82.41277 for the stock.
The latest earnings results from Moderna Inc (NASDAQ: MRNA) was released for 2024-09-30. The net profit margin was -43.84% and return on equity was -17.52% for MRNA. The company reported revenue of $1.86 billion for the quarter, compared to $1.83 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 1.69 percent. For the current quarter, analysts expect MRNA to generate $951.09M in revenue.
